Smith & Nephew plc (NYSE:SNN) Shares Sold by Hantz Financial Services Inc.

Hantz Financial Services Inc. cut its position in shares of Smith & Nephew plc (NYSE:SNN) by 2.5% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 69,657 shares of the medical equipment provider’s stock after selling 1,780 shares during the quarter. Hantz Financial Services Inc.’s holdings in Smith & Nephew were worth $1,712,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of SNN. River Road Asset Management LLC acquired a new position in Smith & Nephew in the 3rd quarter valued at $38,588,000. Dimensional Fund Advisors LP increased its stake in Smith & Nephew by 58.2% in the second quarter. Dimensional Fund Advisors LP now owns 524,602 shares of the medical equipment provider’s stock valued at $12,995,000 after purchasing an additional 193,046 shares during the last quarter. Point72 DIFC Ltd purchased a new position in Smith & Nephew during the third quarter worth about $7,200,000. State Street Corp boosted its stake in Smith & Nephew by 1.3% in the 3rd quarter. State Street Corp now owns 143,846 shares of the medical equipment provider’s stock worth $4,479,000 after buying an additional 1,889 shares during the last quarter. Finally, Raymond James & Associates grew its holdings in Smith & Nephew by 172.1% in the 3rd quarter. Raymond James & Associates now owns 128,854 shares of the medical equipment provider’s stock valued at $4,013,000 after buying an additional 81,500 shares during the period. Institutional investors and hedge funds own 25.64% of the company’s stock.

Smith & Nephew Trading Down 1.1 %

NYSE SNN opened at $25.38 on Friday. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.11 and a current ratio of 2.51. Smith & Nephew plc has a one year low of $23.65 and a one year high of $31.72. The company’s 50 day moving average price is $25.04 and its 200 day moving average price is $27.66.

Analysts Set New Price Targets

SNN has been the topic of several research analyst reports. StockNews.com cut shares of Smith & Nephew from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, November 12th. Deutsche Bank Aktiengesellschaft cut shares of Smith & Nephew from a “buy” rating to a “hold” rating in a research note on Friday, November 1st. Finally, Berenberg Bank cut Smith & Nephew from a “buy” rating to a “hold” rating in a report on Wednesday, November 6th.

Smith & Nephew Profile

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT.